Modified immune cells sniff out cancer, quite literally
Cancer cells produce chemical compounds that healthy cells do not. Researchers have now reprogrammed immune cells to detect that chemical signature and use it as a roadmap straight to the tumor.
One of the most stubborn problems in cancer therapy is not killing tumor cells, something researchers are getting better at all the time, but getting inside them in the first place. Tumors are surrounded by a hostile environment that actively locks immune cells out: impenetrable layers of tissue, inhibitory signaling molecules, a state of profound metabolic exhaustion. Even the most advanced CAR-T cells, immune cells genetically engineered to recognize cancer cells, frequently stall at the edge of the tumor. They can see the target, but they cannot reach it.
New research, reported by Lifespan.io on the basis of a recent study, describes a different approach. Rather than teaching immune cells to recognize a tumor by the proteins on its surface, scientists equipped them with a receptor that responds to metabolites, small molecules released during the intense metabolic activity of tumor cells. Cancer cells burn glucose in a fundamentally different way from normal cells, even when oxygen is plentiful. That Warburg effect, described a century ago, generates a constant stream of specific metabolites in and around the tumor. That stream can now be used as a navigational beacon.
NK cells and T cells as metabolic bloodhounds
The researchers modified both natural killer (NK) cells and cytotoxic T cells with these metabolite-sensing receptors. In mouse models of solid tumors, the modified cells penetrated the tumor more deeply than their unmodified counterparts, and outcomes improved significantly. The combination of metabolic navigation with the existing ability to kill cancer cells directly proved synergistic: the cells not only gained better access, they were also more effective once they arrived.
What sets this apart from earlier approaches is the universality of the signal. Many current immunotherapies rely on tumor-specific proteins that can vary widely from patient to patient and from one cancer type to another. Metabolites such as lactate and other Warburg byproducts are present far more consistently across cancer types. A therapy built around metabolic recognition could therefore be applicable to a broader range of patients than the current generation of personalized immunotherapies.
From mouse to human: the usual hurdles
The results are encouraging, but the research is still at the preclinical stage. Mouse models are notoriously poor predictors of how human tumors will respond, and it remains to be seen whether the metabolic signature of tumors in people is as distinctive as it is in the models used here. On top of that, immune cells operate inside the human body in a far more complex environment, one with more inhibitory signals and far greater variation between patients.
What this research does offer is a conceptual shift: instead of targeting the tumor's structure, you target its metabolic behavior. Whether that proves just as promising in the clinic as it does in the laboratory is something the coming years will have to show.